[ad_1]
Jakarta, CNN Indonesia –
President Director Bio Pharma Honesti Basyir confirmed the price corona vaccine around 200 thousand IDR.
The statement responds to the news about the agreement. Sinovac with Brazil, which will sell the price of the vaccine of around US $ 1.96 per dose or equivalent to Rp. 29 thousand (assuming an exchange rate of Rp. 14,764 per US dollar).
However, Sinovac has denied this price through an official letter sent to Bio Farma.
“The price range is 200 thousand IDR. We clarify the information on the price of the covid-19 vaccine in Brazil to Sinovac. They have sent an official email to Bio Farma, which ensures that the information in the news about the contract of purchase of 46 million doses with a contract value of US $ 90 million with The Brazilian government is not right. Regarding the price of US $ 1.96 per dose, it is not correct, “Honesti said in an official statement on Tuesday. (10/13).
The reason is that, according to Honesti, the shipping cost for each dose is around US $ 2. Honesti revealed in the official letter delivered by Sinovac, there are several factors that determine the price of the covid-19 vaccine. One factor is confidence in investing in phase 3 clinical studies, especially large-scale efficacy trials.
Also, pricing in Indonesia follows the same principles. In other words, the covid-19 vaccine pricing scheme cannot be matched.
Honesti explained to maintain and guarantee the quality of the Covid-19 vaccine from raw materials and others, the Food and Drug Administration (BPOM) will fly to Sinovac China to to visit an audit of the corona vaccine development and production process at the Sinovac facility in Beijing, China.
This visit included LPPOM MUI to conduct a halal audit. BPOM will also ensure that the facilities and production processes of the covid-19 vaccine at Bio Farma comply with the Good Manufacturing Practice (CPOB) standards /Good manufacturing practices (GMP).
Currently, the phase 3 clinical trial of the Covid-19 vaccine is still ongoing in the second week of October 2020.
The most recent data shows that, as of October 9, 2020, 843 volunteers have received the second injection and 449 volunteers are in the blood collection stage after the second injection / are entering the monitoring period.
So far, the phase 3 clinical trial has run smoothly and there have been no reports of serious incidents of post-immunization follow-up (AEFI) due to the injection of the covid-19 vaccine candidate.
[Gambas:Video CNN](age / bir)
[ad_2]
